Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...
Dupixent has already picked up an additional approval as a treatment for severe asthma, and the French drugmaker is also eyeing testing it in phase 2 and 3 trials in chronic obstructive pulmonary ...
Sanofi’s new atopic dermatitis treatment Dupixent has gained EU approval ... as is now a matter of course. Potential in asthma The drug is also set to gain further indications in further ...
GlobalData on MSN5d
Sanofi increases ownership stake partaking in pharma buyback trendSanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.
GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...
Many people with atopic dermatitis also have asthma or allergic rhinitis (nasal allergies ... This is how biologic treatments can help. Dupixent (dupilumab) was the first biologic treatment approved ...
United Health Group’s pharmacy benefit manager, Optum Rx, stopped covering Cole Schmidtknecht’s ‘life-changing’ inhaler, suit ...
Shanon and William Schmidtknecht, of Poynette, say their 22-year-old son Cole was told the cost had jumped from $66 to $539 ...
He managed his symptoms with Advair Diskus — the brand name for fluticasone and salmeterol, medications that help control the symptoms of asthma when taken daily. GSK, the manufacturer of Advair ...
Arizona Attorney General Kris Mayes on Thursday sued drug producer GlaxoSmithKline (GSK) for harm done to asthma patients by discontinuing a long-time product.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback